Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06246110 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
A Phase 2 study of NSCLC, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT06246110: Recruiting Phase 2 study of NSCLC, sponsored by Eikon Therapeutics.
NCT06246110 is a Phase 2 study of NSCLC that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 70 participants, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06246110, a Phase 2 study of NSCLC, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Primary Outcome
Defined AEs that occur during treatment and are deemed to be related EIK1001 or combination with SOC or due to disease progression or toxicity.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG EIK1001
Study Locations (20)
California
- California Cancer Care Associates for Research & Excellence - Fresno
- California Research Institute - Los Angeles
- University of Southern California, Norris Comprehensive Cancer Center - Los Angeles
- Providence St Joseph Hospital, Center for Cancer Prevention and Treatment - Orange
- Sutter Health Institute for Medical Research - Sacramento
Florida
- Bioresearch Partner - Hialeah
- Memorial Cancer Institute - Hollywood
- Mid-Florida Hematology and Oncology Center - Orange
- Orlando Health Cancer Institute - Orlando
- Moffitt Cancer Center - Tampa
Illinois
- Illinois Cancer Specialists - Niles
- Accelacare of Duly - Tinley Park
Kansas
- Health Midwest Oncology Associates of Kansas - Overland Park
- Cancer Center of Kansas - Wichita
Alabama
- Southern Cancer Care - Daphne
Arizona
- Ironwood Cancer and Research Center - Chandler
Colorado
- Rocky Mountain Cancer - Lone Tree
Georgia
- Atlanta Piedmont Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-02-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06246110 shows while recruiting
NCT06246110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (69% lower).
The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06246110 names 20 study sites across 10 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06246110 about?
NCT06246110 is a clinical study titled "A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC". This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
What is the current status of trial NCT06246110?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2024-02-06. Estimated completion is 2027-12.
What conditions does trial NCT06246110 study?
This clinical trial studies the following conditions: NSCLC.
What interventions are being tested in trial NCT06246110?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), EIK1001 (DRUG).
Who is sponsoring clinical trial NCT06246110?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06246110 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06246110's enrollment target sits among peer trials
70 49th of 71 higher than 22 of 71 other NSCLC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NSCLC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI